THE SEROTONIN SYNDROME-ASSOCIATED WITH PAROXETINE, AN OVER-THE-COUNTER COLD REMEDY, AND VASCULAR-DISEASE

被引:88
作者
SKOP, BP [1 ]
FINKELSTEIN, JA [1 ]
MARETH, TR [1 ]
MAGOON, MR [1 ]
BROWN, TM [1 ]
机构
[1] WILFORD HALL USAF MED CTR,DEPT PSYCHIAT,2200 BERGQUIST DR,ST 1,LACKLAND AFB,TX 78236
关键词
DEXTROMETHORPHAN; ENDOTHELIUM; PAROXETINE; SEROTONIN; SEROTONIN SYNDROME; VASCULAR DISEASE;
D O I
10.1016/0735-6757(94)90031-0
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
There is a new, potentially fatal disorder that is infrequently reported. The apparent rareness may be because of a lack of recognition of the syndrome or its predisposing factors. Fluoxetine (Prozac, Dista Products Co, Division of Eli Lilly Co, Indianapolis, IN), sertraline (Zoloft, Roerig Division, Pfizer Inc, New York, NY), and paroxetine (Paxil, SmithKline Beecham Pharmaceuticals, Philadelphia, PA) belong to a new class of antidepressant medication: the serotonin reuptake-inhibitors (SRIs). The relative safety profile of the SRIs has led to their widespread use. However, a syndrome of excessive serotonergic activity, the ''serotonin syndrome'' (SS), has recently been recognized. It is characterized by changes in mental status, hypertension, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor. A high index of suspicion is required to make the diagnosis in these acutely ill patients. The most common agents implicated in SS are the monoamine oxidase inhibitors in combination with L-tryptophan or fluoxetine. A case of a patient with significant peripheral vascular disease who developed SS while taking paroxetine and an over-the-counter cold medicine is reported. There have been no prior reports of this interaction. Discontinuation of the offending agents, sedation, and supportive care are the mainstays of treatment. The interactions of serotonin with platelets and vascular endothelium are also discussed.
引用
收藏
页码:642 / 644
页数:3
相关论文
共 24 条
[11]  
Durson, Mathew, Reverley, Toxic serotonin syndrome after fluoxetine plus carbamazepine, The Lancet, 342, pp. 442-443, (1993)
[12]  
Stack, Rogers, Litter, MONOAMINE OXIDASE INHIBITORS AND ANAESTHESIA, BJA: British Journal of Anaesthesia, 60, pp. 222-227, (1988)
[13]  
Kamei, Mori, Igarashi, Et al., Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs., Res Commun Chem Pathol Pharmacol, 76, pp. 371-374, (1992)
[14]  
Rivers, Horner, Possible lethal reaction between nardil and dextromethorphan., Can Med Assoc J, 103, (1970)
[15]  
Prichard, Smith, Serotonin: receptors and antagonists--summary of symposium., Clin Physiol Biochem, 8, pp. 120-128, (1990)
[16]  
Hourani, Cusack, Pharmacological receptors on blood platelets, Pharmacol Rev, 43, pp. 193-298, (1991)
[17]  
Schror, Braun, Platelets as a source of vasoactive mediators, Stroke, 21, pp. 32-35, (1990)
[18]  
Lucki, Nobler, Frazer, Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat, J Pharmacol Exp Ther, 1, pp. 133-139, (1984)
[19]  
Ku, Coronary vascular reactivity after acute myocardial ischemia, Science, 218, pp. 576-578, (1982)
[20]  
Luscher, Vanhoutte, Endothelium-dependent responses to aggregating platelets and serotonin in spontaneously hypertensive rats, Hypertension, 8, pp. 55-60, (1986)